본문으로 건너뛰기
← 뒤로

Neoadjuvant Chemotherapy in Choroid Plexus Carcinoma: Improving Surgical Safety and Resection Outcomes.

1/5 보강
JPMA. The Journal of the Pakistan Medical Association 📖 저널 OA 36.4% 2022: 0/2 OA 2023: 2/5 OA 2024: 7/9 OA 2025: 5/11 OA 2026: 2/7 OA 2022~2026 2026 Vol.76(1) p. 113-115
Retraction 확인
출처

Charolia MS, Suleman F, Shamim MS

📝 환자 설명용 한 줄

Choroid plexus carcinoma (CPC) is a rare and highly vascular malignant brain tumour that occurs mainly in children.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Charolia MS, Suleman F, Shamim MS (2026). Neoadjuvant Chemotherapy in Choroid Plexus Carcinoma: Improving Surgical Safety and Resection Outcomes.. JPMA. The Journal of the Pakistan Medical Association, 76(1), 113-115. https://doi.org/10.47391/JPMA.26-06
MLA Charolia MS, et al.. "Neoadjuvant Chemotherapy in Choroid Plexus Carcinoma: Improving Surgical Safety and Resection Outcomes.." JPMA. The Journal of the Pakistan Medical Association, vol. 76, no. 1, 2026, pp. 113-115.
PMID 41736349 ↗
DOI 10.47391/JPMA.26-06

Abstract

Choroid plexus carcinoma (CPC) is a rare and highly vascular malignant brain tumour that occurs mainly in children. Complete surgical resection offers the best chance of long-term survival, but this is often difficult due to excessive intraoperative bleeding. Preoperative (neoadjuvant) chemotherapy has been explored as a strategy to shrink the tumour and reduce its vascularity before surgery. In this review, we have summarized the available literature on preoperative chemotherapy in CPC and its effect on surgical outcomes. Reported cases and small series show that platinum- and etoposide-based regimens can decrease tumour size and intraoperative blood loss, allowing safer and more complete resections. However, due to the rarity of CPC and limited data, larger multicentre studies are required to validate these findings and establish standardized treatment protocols.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반